News | February 24, 2026
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
The data highlights its RSV vaccine cuts hospitalizations in older adults
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
Subscribe To Our Newsletter & Stay Updated
